

## AMENDMENTS TO THE SPECIFICATION

**Immediately after the Title of the Invention, please add the following paragraph:**

This application is U.S. National Phase of International Application PCT/AU2004/001675, filed November 26, 2004 designating the U.S., and published in English as WO 2005/052159 on June 9, 2005, which claims priority to Australian Patent No. 2003906613, filed November 28, 2003, both of which are hereby expressly incorporated by reference in their entireties.

**On page 18 of the Specification please replace the following paragraph:**

Furthermore, the peptide fragment may be derived from the C-terminal end of the IL-10 homologue. For example, the fragment may comprise one or more amino to acids, or a combination thereof, of a unique 12 amino acid sequence VSVSVAALSAQR (SEQ ID NO: 11), and in such an example, the peptides may overlap this unique region.

**On page 18-19 of the Specification please replace the following paragraph:**

In preparing antibodies for use in the invention, a protocol such as that set out in the following may be used. The cDNA sequence of the IL-10 homologue or variant or fragment thereof is cloned into a vector, such as pcDNA3.1 *myc*-His to generate a carboxyl terminal *myc*-His tagged IL-10 homologue or expression vector. This vector is then transformed into *E. coli* and the expressed protein affinity purified. The purified IL-10 homologue protein may be used to generate rabbit polyclonal antiserum using methods known in the art, such as, a commercial production service. In addition to whole IL-10 homologue or variant or fragment thereof protein, unique synthetic peptides, such as peptides whose amino acid sequence overlaps all or part of the unique, non homologous C- terminal portion of IL-10 homologue or variant or fragment thereof as (VSVSVAALSAQR) (SEQ ID NO: 11) may be used as immunogens to generate rabbit polyclonal antiserum. The specificity of the resulting antibodies will be determined by immunoblotting against purified IL-10 homologue, human IL10 and cmvIL10 (human IL10 and cmvIL10 are available commercially). Based upon these results, monoclonal antibodies can be generated against whole or a part of the IL-10 homologue.

**On pages 33-34 of the Specification please replace Table 1 with the following Table:**

Primer	Sequence	Pair	Unspliced	Spliced	Spliced
--------	----------	------	-----------	---------	---------

				Intron 1	intron 1 & 2
JAS-53	5'-ACTATTCTAACCGCGGAAG-3' (SEQ ID NO: 2)	JAS-R4	712	636	553
		JAS-R5	803	727	644
JAS-52	5'-CATAAAGGACCACCTACCTGGGA-3' (SEQ ID NO: 3)	JAS-R4	655	579	496
		JAS-R5	746	670	587
JAS-F1	5'-TACAAAGCCGCAGTGTCTCCAGAGGATTACG-3' (SEQ ID NO: 4)	JAS-R1	247	171	N/A
		JAS-B1	346	270	N/A
		JAS-R5	588	512	429
JAS-P3	5'-CAGATTGCAAGATCTCCGCGTCACCTT-3' (SEQ ID NO: 12)	JAS-R4	461	385	302
JAS-R1	5'-CAACAACCAGTCCATGACGCTGCATC-3' (SEQ ID NO: 5)	JAS-F1	247	171	N/A
JAS-B1	5'-GTAGATGGATTCTAGCGTCGAGCGCAT-3' (SEQ ID NO: 6)	JAS-F1	346	270	N/A
JAS-R4	5'-TCCTGAGACAGCCGACTAATCACGGAC-3' (SEQ ID NO: 7)	JAS-53	712	636	553
		JAS-52	655	579	496
		JAS-P3	461	385	302
JAS-R5	5'-TCTCGAGTGCAGATACTCTTCGAGACGG-3' (SEQ ID NO: 8)	JAS-53	803	727	644
		JAS-52	746	620	587
		JAS-F1	588	512	429
JAS-R6	5'-GACCACCGTACCGTCGAGCCACACGGAG-3' (SEQ ID NO: 9)	Probe	N/A	N/A	N/A

**Please add the Abstract provided herewith as the last page of the Specification.**